Comparative Pharmacology
Head-to-head clinical analysis: ANCEF versus ARBLI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANCEF versus ARBLI.
ANCEF vs ARBLI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
First-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
ARBLI (arbaclofen placarbil) is a prodrug of baclofen, a GABA-B receptor agonist. It acts presynaptically to inhibit excitatory neurotransmitter release and postsynaptically to reduce neuronal excitability, leading to muscle relaxation.
1-2 g IV/IM every 8 hours; maximum 6 g/day.
10 mg orally once daily.
None Documented
None Documented
1.5-2 hours in adults with normal renal function; prolongs significantly in renal impairment (up to 30 hours in anuria).
Terminal elimination half-life of 26 hours (range 20-32 h), supporting once-daily dosing; prolonged in hepatic impairment.
Primarily renal (80-90% unchanged by glomerular filtration and tubular secretion); small amounts biliary (<1%) and fecal.
Primarily biliary (>70%) and fecal elimination; renal excretion accounts for <5% of unchanged drug.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic